The results reported today were in healthy male subjects receiving OMS824 once daily for seven days at a dose higher than those previously evaluated in the target-engagement clinical trial. Positron emission tomography (PET) scans were used to measure the binding activity of OMS824 to PDE10 in the brain. An average of 63% occupancy at PDE10 was seen in the basal ganglia, the region of the brain that plays a critical role in cognition. The drug was well tolerated with mild somnolence as the only apparent side effect.
While the level of target engagement seen in this PET trial is significantly higher with lesser side effects than has been reported for any other PDE10 inhibitor in development, a recently completed Phase 1 clinical pharmacokinetic trial with 10 days of OMS824 dosing achieved ~ 50% higher plasma concentrations than in the PET trial, and all side effects were mild and well-tolerated, and most were self-limiting. PET data were not obtained in this pharmacokinetic trial but, based on modeling of all data obtained in the OMS824 Phase 1 program, it is estimated that the drug engaged the PDE10 enzyme at levels substantially greater than 63%. Co is now planning to evaluate a higher dose of OMS824 in the PET trial to confirm this estimate.
Recent OMER News
- Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results • Business Wire • 04/01/2024 08:02:00 PM
- Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024 • Business Wire • 03/27/2024 12:30:00 PM
- Omeros Corporation Announces Upcoming Presentation Detailing Narsoplimab Compassionate Use in Nine Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy • Business Wire • 02/20/2024 02:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 11:05:17 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 01:00:23 PM
- Omeros Corporation Announces Additional Royalty Monetization with DRI Healthcare Trust • Business Wire • 02/01/2024 02:11:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/29/2024 08:26:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 01:11:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/18/2023 02:46:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/16/2023 02:55:18 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:06:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:05:36 PM
- Omeros Corporation Reports Third Quarter 2023 Financial Results • Business Wire • 11/09/2023 09:02:00 PM
- Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2023 • Business Wire • 11/06/2023 01:00:00 PM
- Omeros Announces Online Publication in Advance of ASH Annual Meeting Detailing Narsoplimab Treatment Under Compassionate Use of 15 Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy • Business Wire • 11/03/2023 01:05:00 PM
- Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting • Business Wire • 11/02/2023 01:05:00 PM
- Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer • Business Wire • 10/19/2023 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/16/2023 08:36:07 PM
- Omeros Corporation Provides Update on Interim Analysis of ARTEMIS-IGAN Phase 3 Trial of Narsoplimab in IgA Nephropathy • Business Wire • 10/16/2023 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/27/2023 09:02:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/27/2023 08:56:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/27/2023 08:53:30 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/20/2023 08:47:29 PM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM